FRAX fracture prediction tool underestimates fracture risk in people with HIV

Published: 18 March 2015

The Fracture Risk Assessment Tool (FRAX), an online tool developed by the World Health Organization and used to help guide decisions about who to screen or treat in order to prevent bone fractures, underestimates overall risk of fracture in people living with HIV – even with an adjustment experts have recommended to improve its accuracy for people with HIV – according to an analysis of the Veterans Aging Cohort Study Virtual Cohort (VACS-VC) reported at the recent Conference on Retroviruses and Opportunistic Infections (CROI 2015) in Seattle, USA.

Worse, using the thresholds currently recommended by US guidelines for screening and treatment did not discriminate well between those individuals actually at risk and those not at risk for future fractures, according to Michael Yin from Columbia University, who presented the study findings.

Fractures in people with HIV

The incidence of bone fractures – whether associated with trauma or fragility – is increased in people living with HIV, especially with advancing age. According to a recent meta-analysis of the VACS, the unadjusted risk of fragility fractures was about 38% higher for people living with HIV than for HIV-negative individuals.

This understanding has led to changes in HIV management guidelines. For instance, the most recent HIV Medicine Association guidelines in the US recommend dual energy x-ray absorptiometry (DEXA, or DXA) bone density screening for men and women over age 50. The European AIDS Clinical Society (EACS) also recommends DXA screening for men over 50 and postmenopausal women, but in addition recommends fracture risk assessment using the FRAX tool, without bone mineral density (BMD) assessment, for people with HIV over the age of 40.

As noted, FRAX is a web-based fracture risk calculator that uses easily obtainable clinical risk factors (used with or without BMD) to estimate absolute ten-year risk of having a major osteoporotic (spine, upper arm, wrist or hip) fracture or of having a hip fracture alone. FRAX has been well validated in the general population across many different countries and populations, but there has been a question whether FRAX works equally well at predicting fractures in HIV-positive and HIV-negative individuals.

In several small studies, FRAX scores were not predictive of osteoporosis (bone loss) by DXA score or prevalent fractures in people living with HIV. Since FRAX can underestimate fracture risk in people with HIV, some experts have advised entering 'yes' for the secondary osteoporosis question, to serve as a surrogate for HIV infection – even though HIV is not listed among the known causes of secondary osteoporosis – in order to increase the accuracy of FRAX scores for people with HIV. 

The study

There have been no studies of people with HIV looking at how well FRAX (unadjusted or with the expert-recommended tweak for HIV) predicts incident, or newly diagnosed fractures, which is what the tool was designed to do. So Yin and colleagues designed a study to compare the accuracy of FRAX in HIV-positive versus HIV-negative men aged 50-70 years. They assumed that FRAX would underestimate risk, but that the recommended adjustment would improve accuracy.

For the study they selected a sample of men in the Veterans Aging Cohort Study between age 50 and 70 for whom complete data were available from the year 2000, in order to approximate all but two factors used in FRAX score calculation, since they did not have complete data on secondary osteoporosis causes and parental hip fracture. For this reason, this represented a 'modified FRAX' calculation. (By convention, 'no' was entered for the categories of parental hip fracture and secondary osteoporosis for all participants because of the incomplete data.)

The researchers also had ten-year incident fracture data from 2001 through 2010 for new fractures of the spine, upper arm, wrist and hip to correspond with those fractures that FRAX predicts. The resulting analytic sample included over 24,400 men, with nearly one-third being HIV-positive.

To determine how accurate FRAX estimates were in both the HIV-positive and HIV-negative populations, they looked at the agreement between observed fractures and estimated fracture predictions using the modified FRAX. They assessed the accuracy of the adjusted modified FRAX in people living with HIV, when HIV infection was treated as cause of secondary osteoporosis. They also looked at discrimination, or the ability of the FRAX estimate to discriminate between individuals who would have and who would not have a fracture.

At baseline, the participants' median age was 56 and was similar in both the HIV-positive and HIV-negative groups. However, the men with HIV were more likely to be black, weighed less, drank more alcohol and had a higher prevalence of previous fractures, but reported less current smoking and were less likely to have rheumatoid arthritis than the HIV-negative men.

Major findings

The modified FRAX estimates suggested that over the ten-year period, about 3.0% of the participants would have a fracture at a major osteoporotic site and about 0.3% would have a hip fracture. The actual observed rate was significantly higher: a 4.6% fracture risk at major osteoporotic sites among the men with HIV (vs 3.5% among HIV-negative men) and 1.3% fracture risk at the hip (vs .09%). Both the estimated fracture and the observed fracture rates were higher among HIV-positive than among HIV-negative men.

When HIV was treated as a cause of secondary osteoporosis, the estimates of fracture risk went up by 31% for a major osteoporotic fracture and by about 67% for hip fractures.

The observed fracture versus estimated fracture ratios were 1.6 for HIV-positive men and 1.3 for HIV-negative men (the higher the ratio, the greater the under-estimation). However, the adjustment – treating HIV as a cause of secondary osteoporosis – improved the observed versus estimated fracture ratio to levels similar to those for FRAX in the HIV-negative population. The accuracy was also worse among those individuals with a higher fracture risk. 

Pharmacologic treatment thresholds for FRAX

In the US, the first step for the evaluation of osteoporosis is DXA screening. FRAX is used for individuals who do not meet the DXA criteria for osteoporosis but who have either low bone density or osteopenia (less severe bone loss, with a T-score between -1.0 and -2.5). FRAX calculations are then recommended to see which individuals are at a high enough risk for fractures to justify pharmacologic treatment. The thresholds are set at  >20% formajor osteoporotic fractures or >3% for hip fractures.

In this study population, none of the participants met the criteria for pharmacologic therapy using the threshold of >20% formajor osteoporotic fracture sites. Using the threshold of >3% for hip fractures, 1% of the population – or 74 men – met the criteria.

However, using this threshold would have identified only three out of the 93 individuals who actually had a hip fracture during this period, yielding a specificity of 99% but a sensitivity of only 3%.

"So using this threshold for the modified-FRAX, 71 men would be treated unnecessarily to prevent one fracture – and 97% of men will get a fracture because they remain untreated," Yin said.

Discussion

There were several limitations to the study, the first being that this was a modified FRAX, as the researchers were missing data on two variables used in the tool. In addition, the cohort only included men, which limits the generalizability of the findings to women. Also, although this was a group of men over the age of 50, only 10% of study participants were over the age of 65, and fracture risk rises with increasing age. The researchers also did not explore the impact of hepatitis C in FRAX, though they are doing this currently.

In conclusion, Yin said, "The modified FRAX accuracy is limited for HIV-positive men and the exact role of FRAX for risk stratification in HIV-infected individuals – both for DXA screening and for pharmacologic therapy – requires additional study. "

Reference

Yin M et al. Fracture prediction with modified FRAX in older HIV+ and HIV- men.  2015 Conference on Retroviruses and Opportunistic Infections (CROI), Seattle, abstract 141, 2015.

View a webcast of this presentation.

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.